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 Cardiovascular diseases remain the leading cause of 
death. The majority of these diseases involve a pathogenic 
process: atherosclerosis ( 1 ). Hyperlipidemia is the primary 
atherogenic risk factor ( 1, 2 ). In the plasma, lipids are 
encapsulated particles with apoproteins ( 1 ). High-density 
lipoproteins (HDL) transport lipids from peripheral tissues 
to the liver and, thus, are antiatherogenic ( 1 ). Low-density 
lipoproteins (LDL) are the major type of lipoproteins 
accumulated in the subendothelial matrix and, hence, are 
atherogenic. LDL is derived from very low-density lipo-
proteins (VLDL), which are assembled in and secreted by 
the liver ( 2 ). VLDL assembly starts when apolipoprotein 
B-100 (apo-B100) is translated and translocated into en-
doplasmic reticulum (ER). Maturation of VLDL particles 
undergoes multiple lipidation processes that traverse from 
the ER and post-ER/Golgi compartments ( 2 ). Lipids in-
corporated into VLDL particles undergo continuous 
hydrolysis/reesterifi cation. 
 Carboxylesterase-1 (CES1) in humans and its function-
ally related mouse counterpart (Ces1d) in lipid catabolism 
are implicated in the hydrolysis/reesterifi cation cycle ( 3, 4 ). 
Indeed, higher CES1 activity facilitates VLDL maturation 
( 5 ), and transgenic expression of CES1 leads to increased 
secretion of apoB proteins ( 3 ). Conversely, hydrolysis of 
cholesterol esters by CES1 is linked to cholesterol elimina-
tion ( 6 ). In the classic pathway of bile acid synthesis, choles-
terol is oxidized by cytochrome 7A1 (CYP7A1) ( 7 ), eventually 
converted into bile acids, and secreted by the bile acid 
export pump (BSEP). The secretion of bile acids repre-
sents the net elimination of excessive cholesterol ( 8 ). 
 Abstract  Z-Guggulsterone is a major ingredient in the 
Indian traditional hypolipidemic remedy guggul. A study 
in mice has established that its hypolipidemic effect in-
volves the farnesoid X receptor (FXR), presumably by act-
ing as an antagonist of this receptor. It is generally assumed 
that the antagonism leads to induction of cytochrome P450 
7A1 (CYP7A1), the rate-limiting enzyme converting free 
cholesterol to bile acids. In this study, we tested whether 
Z-guggulsterone indeed induces human CYP7A1. In addi-
tion, the expression of cholesteryl ester hydrolase CES1 
and bile salt export pump (BSEP) was monitored. Contrary 
to the general assumption, Z-guggulsterone did not induce 
CYP7A1. Instead, this phytosterol signifi cantly induced 
CES1 and BSEP through transactivation. Z-Guggulsterone 
underwent metabolism by CYP3A4, and the metabolites 
greatly increased the induction potency on BSEP but not on 
CES1. BSEP induction favors cholesterol elimination, 
whereas CES1 involves both elimination and retention 
(probably when excessively induced). Interestingly, clinical 
trials reported the hypolipidemic response rates from 18% 
to 80% and showed that higher dosages actually increased 
VLDL cholesterol.  Our fi ndings predict that better hypo-
lipidemic outcomes likely occur in individuals who have 
a relatively higher capacity of metabolizing Z-guggulsterone 
with moderate CES1 induction, a scenario possibly achieved 
by lowering the dosing regimens. —Yang, D., J. Yang, D. Shi, 
D. Xiao, Y-T. Chen, C. Black, R. Deng, and B. Yan.  Hypolipi-
demic agent Z-guggulsterone: metabolism interplays with 
induction of carboxylesterase and bile salt export pump. 
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inserted into the pGL3 basic luciferase vector to prepare reporter 
CES1A1-7714Luc. This construct was then used as the template to 
prepare reporters: CES1A1-6981Luc, CES1A1-3582Luc, CES1A1-
3432Luc, and CES1A1-2932Luc with the same antisense primer 
(CES1A1-21XhoIa) but different sense primer ( Table 1 ). The re-
porters CES1A1-9622Luc and CES1A1-9332Luc contained addi-
tional upstream sequences. To prepare these constructs, human 
genomic DNA was used as the template with primers CES1A1-
4777a and CES1A1-9622Mlus or CES1A1-9333MluIs. The respec-
tive fragments were digested with Mlu I and Spe I (an internal site 
in the fragments). The digested fragments were then ligated to the 
reporter CES1A1-7714Luc pretreated with the same endonu-
cleases. The CES1A1 guggulsterone element reporter was prepared 
by inserting the oligonucleotides (5 ′ -CACA ATCTGCAGAGTC-
ATCATG AAG-3 ′ ) into the pGL3 promoter vector at the Nhe I and 
Xho I sites. All constructs were confi rmed by sequencing. The re-
porter assays were performed as described previously ( 12 ). 
 Metabolism of Z-guggulsterone 
 Metabolism was conducted with recombinant CYPs (1 pmol) 
and pooled human liver microsomes (20   g) in a total volume of 
100   l ( 18, 19 ). Preliminary studies were performed to deter-
mine conditions supporting the linear rate. Z-Guggulsterone was 
dissolved in acetonitrile, and the fi nal concentration of the sol-
vent was 0.1%. After 10 min preincubation at 37°C, reactions 
were initiated by adding the NADPH-regenerating system (NRS) 
and then were incubated for 40 min. The reactions were termi-
nated by two volumes of ice-cold acetonitrile containing the 
internal standard spironolactone (10   g/ml), followed by cen-
trifugation. For the inhibition assay, the prereaction mixtures 
contained a CYP inhibitor at previously reported concentrations 
( 20 ). The metabolism was monitored for the disappearance of 
Z-guggulsterone by LC-MS/MS (API 3200) ( 19 ). Detection of the 
analytes was performed in positive ion mode using the mass 
transitions of  m/z 313.2 → 97.0 for Z-guggulsterone and  m/z 
416.6 → 341.2 for IS. Injection analysis was performed at a fl ow 
rate of 200   l/min to obtain optimum source parameters. The 
assay was linear from 1.04 to 416.27 ng/ml for Z-guggulsterone. 
 Purifi cation of metabolites 
 Reactions were set up in a total volume of 1 ml with CYP3A4. 
The supernatants were separated on a Chromolith SpeedROD 
column RP-18e (Merck, Germany) by a gradient mobile phase 
made of 0.1% aqueous formic acid (A) and acetonitrile (B). The 
mobile phase started with 10% acetonitrile for 2 min, 15% for 
5 min, 70% for 3 min, 30% for 4 min, and 10% for 1 min with the 
fl ow rate of 2 ml/min. The metabolites were detected by a diode 
array detector at 240 nm. The concentrated metabolites were 
analyzed by HPLC, and the concentrations were estimated ac-
cording to the curve generated with Z-guggulsterone at various 
concentrations. The metabolites were analyzed for the mass-
to-charge ratios by a Q-Star Elite time-of-fl ight mass spectrometer 
(Applied Biosystems/MDS SCIEX). The LC conditions were the 
same as described above but with a reduced fl ow rate (0.5 ml/
min). Analytic parameters were as follows: injection volume, 20   l; 
column temperature, 30°C; DAD range, 210–400 nm with 240 as 
the detection wavelength; ionization mode, ESI+; scan range, 
220–500 amu; and scan rate, 1 scan/s. 
 Mouse hepatocyte culture and treatment 
 Primary mouse hepatocytes were isolated from 9-week-old 
CD-1 mice (male) by a modifi ed two-step collagenase digestion 
method, essentially as described previously ( 21 ). Hepatocytes 
were dispersed from the digested liver in Williams’ Medium E 
(Sigma-Aldrich, St. Louis, MO) without collagenase and washed 
by low-speed centrifugation (100–150  g , 5 min) three times. He-
patocytes were suspended in Williams’ Medium E containing 
 Increased bile acid synthesis has long been explored for 
the development of drugs with cholesterol-lowering activity. 
The biliary secretion has a large capacity and is equally 
effective in eliminating both endogenous and dietary cho-
lesterols. For quite some time, guggul has gained interest 
worldwide ( 9–11 ). Originally described in the Indian tra-
ditional medicine Ayurveda, guggul has been used for 
thousands of years to treat conditions such as atheroscle-
rosis ( 9, 12 ). The hypolipidemic activity has been con-
fi rmed in multiple animal models ( 9 ). Human clinical trials, 
however, produced inconsistent results. Some clinical 
trials reported that guggul lowered plasma cholesterol 
by 20–30% and triglycerides by 10–20%, with the response 
rate being as high as 80% ( 9, 13, 14 ). Other trials, however, 
did not detect the same level of effectiveness ( 10, 11 ). 
 Nonetheless, Z-guggulsterone is recognized as the major 
active ingredient. Its hypolipidemic activity in mice requires 
the farnesoid X receptor (FXR) ( 15 ). This phytosterol is 
an antagonist of FXR, and such antagonism is assumed to 
accelerate bile acid synthesis by inducing CYP7A1. To 
directly test this hypothesis, human primary hepatocytes 
were treated with Z-guggulsterone, and the expression 
of CYP7A1 was determined. In addition, the expression of 
CES1 and BSEP was monitored. Contrary to the general 
assumption, Z-guggulsterone was an inducer of CES1 and 
BSEP but not of CYP7A1. In addition, Z-guggulsterone was 
metabolized, and the metabolites differentially altered 
CES1 and BSEP induction. Our fi ndings predict that the 
hypolipidemic activity of Z-guggulsterone depends on two 
important interplays: CES1 induction versus CYP7A1 
activity, and the metabolism of Z-guggulsterone versus 
the relative inducibility between CES1 and BSEP. 
 EXPERIMENTAL PROCEDURES 
 RT-qPCR 
 Human primary hepatocytes were obtained from the Liver 
Tissues Procurement and Distribution System (University of 
Minnesota) or CellzDirect (Pittsboro, NC). The use of the human 
samples was approved by the Institutional Review Board. Hepato-
cytes and hepatoma cells (Huh7) were cultured and treated with 
Z-guggulsterone, chenodeoxycholic acid (CDCA), or both as de-
scribed previously ( 12 ). The mRNA levels were determined with 
TaqMan assays ( 16 ). The assay identifi cation numbers were CES1, 
Hs00275607_m1; CYP7A1, Hs00167982_m1; BSEP, Hs00184824_
m1; GAPDH, 4352934E; and RNA polymerase II, Hs00172187_m1. 
The CES1 probe recognized both CES1A1 and CES1A2, and both 
enzymes are identical, although encoded by distinct genes ( 17 ). 
 Reporter assays 
 The BSEP guggulsterone element reporter and the FXR expres-
sion construct were described elsewhere ( 12 ). The CES1A1 report-
ers containing the promoter and its upstream sequence at varying 
lengths were prepared by inserting the corresponding genomic 
fragment into the pGL3 basic luciferase vector at the Mlu I and 
Xho I sites. All genomic fragments were generated by PCR with 
high-fi delity Platinum Taq DNA polymerase. The primer sequences 
are listed in  Table 1 .  Initially, human genomic DNA from the pla-
centa was used as the template for the amplifi cation of the genomic 
fragment from -7714 to -21 (from the initial translation codon) 
with primers CES1A1-21XhoIa and 7714MluIs. This fragment was 
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Interplay between CES1 and BSEP induction by Z-guggulsterone 531
by increasing bile acid synthesis through inducing CYP7A1. 
On the other hand, rats fed with guggul herb extract did 
not show increased expression of CYP7A1 ( 26 ). Neverthe-
less, we made an effort to determine whether Z-guggulster-
one induces human CYP7A1. Human primary hepatocytes 
were treated with Z-guggulsterone, and the expression was 
determined. CDCA, a known suppressor of CYP7A1 ( 27 ), 
was included in this study as a negative control. Contrary 
to the general assumption, Z-guggulsterone caused a 20% 
decrease of CYP7A1 mRNA ( Fig. 1B ),  although the de-
crease did not reach statistical signifi cance. As expected, 
CDCA signifi cantly decreased CYP7A1 mRNA ( Fig. 1B ). 
The decrease was partially reversed by Z-guggulsterone 
35% percoll. The resulting cell pellet was then suspended in 
Williams’ Medium E containing 10% fetal bovine serum, insulin-
transferrin-sodium selenite (ITS) supplement, and dexametha-
sone (100 nM). Cell viability was determined by trypan blue 
exclusion. Hepatocytes were then plated onto collagen-coated 
12-well culture plates. The cells were allowed to attach for 4 h at 
37°C in a humidifi ed chamber with 95%/5% air/CO 2 . Culture 
plates were then gently swirled, and the medium containing un-
attached cells was aspirated. Fresh medium (free serum) was 
added to each well, and the cultures were returned to the humidi-
fi ed chamber. Hepatocytes were cultured in the same medium 
for 48 h, but the medium was changed at 24 h. Thereafter, hepato-
cytes were cultured in DMEM containing treatment chemicals at 
appropriate concentrations for 48 h; the treatment medium was 
replaced once at 24 h. Treated hepatocytes were collected in RIPA 
buffer for Western blotting . Otherwise, hepatocytes were collected 
in Tris-HCl (50 mM, pH 7.4), and lysates were prepared by sonica-
tion as described previously ( 21 ). All mice were allowed free access 
to Purina Rodent Chow 5001 and water, and the use of animals was 
approved by the Institutional Animal Care and Use Committee. 
 Electrophoresis-coupled activity determination 
 Nondenaturing gel electrophoresis for staining esterase activ-
ity was conducted as described previously ( 22 ). Cell lysates (5 or 
20   g) was solubilized with 0.2% Lubrol and subjected to electro-
phoresis with a 3% acrylamide stacking gel and a 7.5% acrylam-
ide separating gel. After electrophoresis, the gels were washed for 
1 h in 100 mM potassium phosphate buffer (pH 6.5), followed by 
incubating in the same buffer containing 1-naphthylacetate 
(5 mM) and 4-benzolamino-2,5-dimethoxybenzenediazonium 
chloride hemi (zinc chloride) salt, usually termed Fast Blue RR 
(0.4 mg/ml). The staining of esterases by this method is based on 
the formation of a black, insoluble complex between 1-naphthol 
hydrolyzed from 1-naphthylacetate and Fast Blue RR. 
 Other analyses 
 Electrophoretic mobility shift assay (EMSA) was performed as 
described previously ( 21, 23 ). Western blotting was detailed else-
where ( 19, 24 ). Preparation of CES1 antibody against a peptide 
was described previously ( 25 ). The antibody (PC-064) against 
BSEP (mouse and human) was purchased from Kamiya Biomedi-
cal Co. (Seattle, WA), the antibody against human CYP7A1 
(ab79847) from Abcam, Inc. (Cambridge, MA), and the antibody 
against mouse cyp7a1 from Cosmo Bio Co. (Western Carlsbad, 
CA). Signifi cant differences were determined by one-way ANOVA 
followed by a Duncan’s multiple comparison test ( P < 0.05). 
 RESULTS 
 Z-Guggulsterone induces CES1 and BSEP 
but not CYP7A1 
 It is generally assumed that Z-guggulsterone exerts hy-
polipidemic activity based on a feed-back mechanism ( 7 ) 
 TABLE 1. Sequences of primers for reporter constructs 
Primer Sequence Reporter
CES1A1-21XhoIa 5 ′ -tcggggcctgcgaggtctcttgcagttca-3 ′ All promoter reporters
CES1A1-7713MluIs 5 ′ -taaggtggatggattacctgaggtcaggagt-3 ′ CES1A1-7714Luc
CES1A1-6980MluIs 5 ′ -ttgcatgtcaaagtgtcagaatggagaaat-3 ′ CES1A1-6981Luc
CES1A1-3582MluIs 5 ′ -ttattgcttacagctgaagtg-3 ′ CES1A1-3582Luc
CES1A1-3432MluIs 5 ′ -tcaggcaaaacctaggagtgg-3 ′ CES1A1-3432Luc
CES1A1-2931MluIs 5 ′ -tccagcctgcacgtggctaga-3 ′ CES1A1-2932Luc
CES1A1-4777a 5 ′ -catagctagccaccctcaatggcgcaaaca-3 ′ 1A19622 and 9332Luc
CES1A1-9622MluIs 5 ′ -tgacacgcgtaccaactcagtccagattcccccagggcag-3 ′ CES1A1-9622Luc
CES1A1-9332MluIs 5 ′ -tgacacgcgtaagagctcgctgtgctccatgaatggggtg-3 ′ CES1A1-9332Luc
 Fig.  1. Effect of Z-guggulsterone on the expression of CES1, 
CYP7A1, and BSEP. (A) Chemical structure of Z-guggulsterone. 
(B–D) Regulated expression in human primary hepatocytes. Hepa-
tocytes (n = 4–8) were treated with Z-guggulsterone (10   M), 
CDCA (10   M), or both for 24 h. DMSO (0.1%) was used as the 
control. The mRNA levels of CES1, CYP7A1, BSEP, GAPDH, or 
polymerase II by Taqman probes. Columns labeled with a different 
letter were statistically signifi cant ( P < 0.05). To determine the 
changes in the protein level, lysates (0.5 µg for CES1 and 20 µg for 
CYP7A1 or BSEP) from pooled samples (n = 4) were resolved by 
7.5% SDS-PAGE and transferred electrophoretically to nitrocellu-
lose membranes. The blots were incubated with an antibody against 
CYP7A1, CES1, or BSEP and then developed with chemilumines-
cent substrate and reprobed by GAPDH antibody. The signal was 
captured by Carestream 2200 PRO Imager. 
 at Univ of Rhode Island, on Novem
ber 19, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
532 Journal of Lipid Research Volume 53, 2012
Initially, concentration-dependent induction was deter-
mined in this line. As shown in  Fig. 2A ,  Z-guggulsterone 
induced CES1 and BSEP mRNA in a concentration-
dependent manner; however, the magnitude of induc-
tion varied markedly. Both genes were induced comparably 
at lower concentrations, but CES1 mRNA was induced 
to a signifi cantly greater extent at 10 and 20 µM. All data 
points on CES1 induction signifi cantly differed from each 
other ( P < 0.05), except those between 0.5 and 1 µM. Like-
wise, all concentrations caused statistically signifi cant in-
duction of BSEP. However, the magnitudes of the inductions 
between 0.5 and 1 µM did not differ signifi cantly, and nei-
ther did those among 5, 10, and 20 µM. Next, we tested 
whether actinomycin D, a transcriptional inhibitor, abol-
ishes the induction of both CES1 and BSEP. Huh7 cells 
were treated with Z-guggulsterone in the presence or ab-
sence of actinomycin D. As shown in  Fig. 2B , cotreatment 
( Fig. 1B ). The level of CYP7A1 protein showed a pattern of 
changes similar to the level of CYP7A1 mRNA. In contrast 
to the suppression of CYP7A1, Z-guggulsterone signifi -
cantly induced both CES1 and BSEP mRNA with BSEP 
( Fig. 1C, D ). The fold of induction of BSEP was higher 
than that of CES1 in the primary hepatocytes ( P < 0.05). 
Cotreatment with CDCA synergistically increased BSEP 
induction but slightly decreased CES1 induction ( Fig. 1C, D ). 
As seen with CYP7A1, the levels of CES1 and BSEP pro-
teins exhibited patterns of changes similar to those of the 
respective mRNA levels. 
 Activation of the CES1A1 promoter 
 We have shown that Z-guggulsterone induces BSEP 
through transactivation ( 12 ). Next, we tested whether 
transactivation is also involved in CES1 induction. Huh7 
cells (a human hepatic line) were used for this study. 
 Fig.  2. Stimulation of the CES1A1 promoter. (A) Concentration-dependent induction of CES1 and BSEP 
Huh7 cells were treated with Z-guggulsterone (Gugg) at various concentrations (0–20 µM) for 24 h, and 
then the levels of CES1 and BSEP mRNA were determined as described above. An asterisk indicates statistical 
signifi cance of a treatment over solvent control, and an alpha indicates statistical signifi cance between two 
columns linked by a line ( P < 0.05). (B) Effect of actinomycin D (Act D) on induction. Huh7 cells were 
treated with Z-guggulsterone (5   M) for 24 h in the absence or presence of actinomycin D (1   M), and the 
levels of CES1 and BSEP mRNA were determined. An asterisk indicates statistical signifi cance of a treatment 
over solvent control ( P < 0.05). (C) Activation of CES1A1 reporters. Huh7 cells were seeded in 48-well plates. 
After an overnight incubation, the cells were transfected with a reporter (50 ng) along with 5 ng of the null-
Renilla luciferase plasmid. The transfected cells were treated with Z-guggulsterone (10   M) or the same 
volume of DMSO for 24 h. Luciferase activities were determined with a dual-luciferase reporter assay. Data 
in this fi gure are from three separate experiments. 
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contained three copies. Nevertheless, EMSA with nuclear 
extract from Z-guggulsterone treated Huh7 cells detected 
a shifted band with the CES1A1 element. This binding was 
competed effectively by the corresponding nonlabeled 
element ( Fig. 3B ). In contrast, the mutant element (5 ′ -CA-
CAAT G T A C T GAG GA ATCATGAAG-3) had no competi-
tive effect ( Fig. 3B ). 
 Metabolism by CYP3A4 
 As described in  Figs. 1 and 2 , BSEP mRNA was induced 
higher in primary hepatocytes, whereas CES1 mRNA was 
induced comparably or higher in Huh7 cells, depending 
on the concentrations. One explanation is that primary 
hepatocytes express higher basal levels of CES1 and, thus, 
the inducibility is lower. Another explanation is that pri-
mary hepatocytes, but not Huh7 ( 28 ), effectively metabolize 
Z-guggulsterone. To test whether Z-guggulsterone actually 
undergoes metabolism, incubations were performed with 
pooled human liver microsomes in the presence or absence 
of the NADPH-regenerating system. This system is required 
for reactions catalyzed by CYPs and fl avin monooxygenases 
( 28 ). As shown in  Fig. 4A ,  the reaction incubated without 
NRS, like zero-minute incubation, yielded a peak with a re-
tention time of 7.92 min (i.e., Z-guggulsterone). This peak, 
with actinomycin D completely abolished the induction of 
both CES1 and BSEP, suggesting that Z-guggulsterone 
induces CES1, like BSEP ( 12 ), through transactivation. 
We next tested whether Z-guggulsterone stimulates the 
promoter of CES1A1, the predominant form of the 
CES1 genes ( 17 ). As shown in  Fig. 2C , all reporters were 
activated by Z-guggulsterone, except reporters CES1A1-
3432luc and CES1A1-2932Luc. The maximum activation 
was 6-fold and occurred with the reporter CES1A1-3582-
Luc ( Fig. 2C ). CES1A1-3432luc, the immediate reporter 
shorter than CES1A1-3582Luc, no longer responded to 
Z-guggulsterone, suggesting that this 150-bp genomic 
fragment (-3582 to -3432) supports the transactivation. 
 To precisely specify the sequence for the transactiva-
tion, element reporters (20–25 bases each) were prepared 
to span the entire region with overlapping sequence. 
Among the element reporters, only one reporter, desig-
nated CES1A1Gugg-Luc, responded to Z-guggulsterone 
( Fig. 3A ).  This and the BSEPGugg-Luc reporter were 
tested for the activation as a function of Z-guggulsterone. 
As shown in  Fig. 3A , the CES1A1 element reporter was 
activated much higher, except at the 20 µM data point 
( Fig. 3A ). Note that the CES1 reporter contained only a 
single copy of the element, whereas the BSEP reporter 
 Fig.  3. Characterization of CES1A1 guggulsterone element. (A) Stimulation of the CES1A1 and BSEP ele-
ment reporters. Reporter assays were performed as described above but with element reporters. An asterisk 
indicates statistical signifi cance of a treatment over solvent control, and an alpha indicates statistical signifi -
cance between two columns linked by a line ( P < 0.05). (B) EMSA analysis. Nuclear extracts (5   g) from 
Huh7 cells treated with Z-guggulsterone (10   M) were incubated with a biotinylated probe (0.01 pmol) for 
20 min. In the competition assay, nuclear extracts were preincubated with the unlabeled probe or mutant at 
50× (+) or 100× (++) excess for 20 min, and then incubated with the biotinylated probe. The protein-DNA 
complexes were electrophoretically resolved and detected with streptavidin-conjugated horseradish peroxi-
dase and chemiluminescent substrate. 
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(Fura) and ketoconazole (Keto), all inhibitors caused a 
10–20% decrease in the metabolism ( Fig. 4B ). Ketoconazole 
caused complete inhibition, whereas the CYP1A2 inhibitor 
furafylline caused no inhibition. Isoform-specifi c substrates 
were used to confi rm the activity of each inhibitor. 
 The inhibition study demonstrated that multiple CYPs 
metabolized Z-guggulsterone, with the CYP3A4 being the 
most active. To directly test this possibility, recombinant 
CYPs were tested for metabolism. Consistent with the inhi-
bition study, CYP3A4 had the highest activity ( Fig. 4C ). 
Moderate metabolism was detected with CYP1A2, 2A6, 
and 2B6; slight metabolism was detected with CYP2C19 
and 2D6; and no metabolism was detected with CYP2C8, 
2C9, and 2E1 ( Fig. 4C ). Interestingly, CYP1A2 was the sec-
ond most active toward Z-guggulsterone, although the cor-
responding inhibitor showed no activity ( Fig. 4B ). Specifi c 
substrates for each CYP were included to verify the catalytic 
activity of each recombinant CYP. 
 Purifi cation of major metabolites 
 To determine whether the metabolism alters the in-
duction potency, we purifi ed several major metabolites. 
Initially, we performed a time-course study to determine 
the kinetics of the metabolism by recombinant CYP3A4. As 
shown in  Fig. 5A ,  the parent compound was disappeared 
by   70% within 30 min of incubation. Prolonged incuba-
tion further increased the metabolism. The metabolite 
profi le generated by CYP3A4 was very similar to that gen-
erated by liver microsomes ( Figs. 4A and 5A ), confi rming 
that this CYP is the primary enzyme for the metabolism. 
Interestingly, the 30 min incubation produced similar 
amounts of M1 and M4; however, prolonged incubation 
produced more M1 than M4 ( Fig. 5A ). To this end, we 
purifi ed M1, M2, M3, and M4 to homogeneity. As shown 
in  Fig. 5B–E , all purifi ed metabolites produced a single 
peak with a predicated retention time. Mass spectrometry 
revealed that M1 was at  m/z 345 and the other three me-
tabolites at 329. Z-Guggulsterone had a mass-to-charge ra-
tio of 313. Therefore, M1 represented an addition of two 
hydroxyl groups, whereas the others resulted from an 
addition of a single hydroxyl group. 
 Induction potency of major metabolites 
 To determine whether the metabolites and Z-guggulster-
one differ in the induction potency, RT-qPCR and re-
porter assays were performed. The concentrations of the 
metabolites were estimated based on the area under the 
curve. This study included all major metabolites except 
M2, which was not suffi cient to generate the standard-
ized concentration (2 µM). Compared with Z-guggulster-
one, all metabolites caused signifi cant increases in the 
level of BSEP mRNA ( Fig. 6A ),  with M3 causing the high-
est increase (> 3-fold). In contrast, the magnitude of 
changes in CES1 mRNA was much less. Compared with 
Z-guggulsterone, M1 caused a 47% increase, M3 caused a 
12% decrease, and M4 caused a 22% increase in CES1 
induction ( Fig. 6A ). All metabolites tested showed sig-
nifi cantly higher induction of BSEP than CES1 mRNA 
( Fig. 6A ). 
however, disappeared by   90% when the incubation was 
performed in the presence of NRS ( Fig. 4A ). At the same 
time, several metabolite peaks appeared with a retention 
time of 4.69 min (M1), 5.60 (M2), 5.92 (M3), and 6.56 
(M4), respectively. M3 was the most abundant ( Fig. 4A ). 
 The majority of oxidations are catalyzed by the CYP system 
( 28 ). We next tested whether one or more CYPs metabolize 
Z-guggulsterone. Incubations were conducted with pooled 
microsomes but in the presence of a CYP inhibitor. A total of 
nine inhibitors were used, including furafylline (CYP1A2), 
pilocarpine (CYP2A6), thio-tepa (CYP2B6), quercetin 
(CYP2C8), sulfaphenazole (CYP2C9), ticlopidine (CYP2C19), 
quinidine (CYP2D6), chlormethiazole (CYP2E1), and keto-
conazole (CYP3A4/5). With the exceptions of furafylline 
 Fig.  4. Metabolism of Z-guggulsterone. (A) Chromatograms gen-
erated by pooled human liver microsomes. The incubations were 
performed at 37°C in a total volume of 100   l containing pooled 
human liver microsomes (20   g) and Z-guggulsterone (10   M) in 
the presence of NRS. The incubations lasted for 90 min. The 
elution trace was generated at 240 nm by injecting 20   l superna-
tants. (B) Inhibited metabolism of Z-guggulsterone. Z-guggulster-
one (10   M) was metabolized by microsomes (20   g) in the 
presence or absence of a CYP inhibitor: 50   M furafylline, 100   M 
pilocarpine, 75   M thio tepa A, 10   M quercetin, 20   M sulfa-
phenazole, 1   M ticlopidine, 10   M quinidine, 100   M chlorme-
thiazole, or 1   M ketoconazole. The reactions lasted for 40 min. 
The disappearance of Z-guggulsterone was monitored. The per-
centage of inhibition was calculated. (C) Metabolism by recombi-
nant CYPs. The incubations were performed with a recombinant 
CYP (1 pmol) and Z-guggulsterone (10   l) for 40 min. All experi-
ments were conducted twice with each in triplicate. 
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whereas the maximal change in the activation by M1 was 
  2-fold ( Fig. 6B ). To further determine whether CYP3A4-
based metabolism of Z-guggulsterone differentially alters 
BSEP and CES1 induction, Huh7 cells were transfected 
with CYP3A4 or the vector, treated with Z-guggulsterone 
(5 µM), and then analyzed for the induction of CES1 
and BSEP mRNA. As shown in  Fig. 6C , cotransfection of 
CYP3A4, compared with the vector, signifi cantly increased 
BSEP but not CES1 induction. 
 Effect of Z-guggulsterone on the expression of mouse 
bsep, cyp7a1, and carboxylesterases (ces) 
 To determine whether Z-guggulsterone modulates the 
expression of the corresponding mouse genes, mouse 
primary hepatocytes were treated with Z-guggulsterone, 
CDCA, or both. As shown in  Fig. 7A ,  Z-guggulsterone sig-
nifi cantly induced bsep but not cyp7a1, and inductions 
were not affected by CDCA cotreatment. These responses 
were consistent with the responses on the expression of 
BSEP and CYP7A1 in rats fed with guggul extract ( 26 ). 
 We next tested the activation of CES1 and BSEP element 
reporters by various metabolites. The results are summa-
rized in  Fig. 6B . The changes in element reporter activa-
tion, compared with those in the induction of CES1 and 
BSEP mRNA, had several important differences. First, all 
metabolites showed increases in the activation of the ele-
ment reporters, which was not true in mRNA induction 
( Fig. 6A, B ). For example, metabolite M3 actually caused a 
slight decrease in the induction of CES1 mRNA. Second, 
between CES1A1 and BSEP, metabolites generally caused 
less difference in the activation of the element reporters 
than in induction of the mRNA ( Fig. 6A, B ). For example, 
metabolite M1 caused much higher increases in the induc-
tion of BSEP mRNA than CES1 mRNA, whereas this me-
tabolite caused similar increases in the activation of both 
element reporters ( Fig. 6A, B ). And third, the overall 
changes in the CES1 element reporter activation were 
greater than those in the induction of CES1 mRNA. For 
example, compared with Z-guggulsterone, the maximal 
change in the induction by M1 was 47% increase ( Fig. 6A ), 
 Fig.  5. Analyses of metabolites by HPLC and LC-MS. (A) Time-course metabolism by CYP3A4. The incubations were performed at 37°C 
with 1 pmol CYP3A4 and 10   M Z-guggulsterone for 0–120 min. The HPLC elution trace was generated at 240 nm. (B–E) HPLC chromato-
gram and full scan of metabolites M1, M2, M3, and M4, respectively. 
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Z-guggulsterone, like the induction of BSEP, was achieved 
by transactivation ( Fig. 2 ). The transactivation depended 
on a particular genomic sequence designated as the 
CES1A1 guggulsterone element ( Fig. 3A ). Coincidently, both 
CES1A1 and BSEP guggulsterone response elements con-
tain an  a ntioxidant  r esponse  e lement (ARE) and an AP-1 
site ( Fig. 8A ).  However, the CES1A1 ARE is orientated in 
an opposite direction to that of BSEP ( Fig. 8A ). Also, the 
CES1A1 AP-1 site (AGAGTCA) slightly differs from that of 
BSEP ( T GA A TCA) ( Fig. 8A ). More importantly, these two 
elements differentially responded to Z-guggulsterone and 
its metabolites, particularly metabolite M3 ( Fig. 6B ). Com-
pared with Z-guggulsterone, M3 increased the activation 
of the BSEP reporter from 2.6- to 7.3-fold, whereas the in-
crease was much less in the activation of the CES1A1 re-
porter from 3.2- to 4.3-fold ( Fig. 6B ). On the other hand, 
similar responses were detected between the reporter acti-
vation and mRNA induction of BSEP ( Fig. 6A, B ), whereas 
the reporter activation of CES1 was much higher than the 
corresponding mRNA induction ( Fig. 6A, B ). One expla-
nation is that the BSEP element provides the primary 
mechanism for BSEP induction by Z-guggulsterone, 
whereas the CES1A1 element represents one of the mech-
anisms for CES1 induction. 
 Clearly, the metabolism of Z-guggulsterone is deter-
mined largely by CYP3A4. The metabolite profi le generated 
As expected, CDCA, a weak activator of mouse fxr ( 26 ), 
caused little changes in the expression of bsep or cyp7a1 
( Fig. 7A ). Next we tested whether these treatments alter 
the expression of mouse carboxylesterases. In terms of the 
number of carboxylesterase genes, mice have almost three 
times as many as humans ( 29 ). The relative level of car-
boxylesterases can be indirectly determined by nondena-
turing electrophoresis, followed by staining for hydrolytic 
activity with 1-naphythalacetate ( 22 ). This standard sub-
strate can be hydrolyzed by many carboxylesterases. As 
shown in  Fig. 7B (left), both CDCA and Z-guggulsterone 
markedly induced several major mouse carboxylesterases, 
such as ces2e and ces2c, but not many others, such as 
ces1d (the mouse counterpart of human CES1). The iden-
tity of some of the electrophoretically distinct mouse car-
boxylesterases remains to be established. As expected, 
Z-guggulsterone signifi cantly increased hydrolysis by CES1 
but much less so by CES2 ( Fig. 7B , right). Cotreatment 
with CDCA slightly decreased the increased hydrolysis of 
CES1 by Z-guggulsterone. 
 DISCUSSION 
 This study has shown that Z-guggulsterone signifi cantly 
induced CES1 and BSEP. The induction of CES1 by 
 Fig.  6. Functional characterization of the metabolites. (A) Differential induction of CES1 and BSEP Huh7 
cells were treated with Z-guggulsterone (2   M) or a metabolite (2   M) for 24 h. The mRNA levels of CES1 
and BSEP were determined. An asterisk indicates statistical signifi cance of a metabolite over Z-guggulster-
one, and an alpha indicates statistical signifi cance between two columns linked by a line ( P < 0.05). (B) Dif-
ferential activation of CES1 and BSEP element reporters. Huh7 cells were seeded in 48-well plates. After 
overnight incubation, the cells were transfected with a reporter (50 ng) and 5 ng of the null-Renilla lu-
ciferase plasmid. The transfected cells were treated with Z-guggulsterone (2   M), a metabolite (2   M), or 
the same volume of DMSO for 24 h. The reporter luciferase activities (fi refl y) were normalized according to 
the null-Renilla luciferase activities. An asterisk indicates statistical signifi cance of a metabolite over Z-gug-
gulsterone, and an alpha indicates statistical signifi cance between two columns linked by a line ( P < 0.05). 
(C) Effect of CYP3A4 on the induction of CES1 and BSEP. Huh7 cells were seeded in 24-well plates at a den-
sity of 1.5 × 10 5 and cultured overnight. The cells were transfected with a CYP3A4 expression construct or the 
corresponding vector (0.5 µg). The transfected cells were cultured for 24 h and then treated with Z-guggul-
sterone at 5   M for 24 h. Total RNA was isolated and analyzed for the levels of CES1 and BSEP mRNA. The 
data were collected from three separate experiments. * P < 0.05. 
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contributes less, if any, to the hepatic metabolism of Z-
guggulsterone. Another interesting observation was that 
CYP3A4 produced various metabolites ( Fig. 5A ). Most of 
them resulted from addition of a single hydroxyl group 
( Fig. 5C–E ). In contrast, the formation of M1 resulted 
from addition of two hydroxyl groups ( Fig. 5B ). Prolonged 
incubation increased the production of M1 but propor-
tionally decreased M4 ( Fig. 5A ), suggesting that M4 is a 
substrate of CYP3A4 to produce M1 ( Fig. 5A ). 
 Although the purifi ed metabolites generally increased 
the induction of both CES1 and BSEP, the magnitude was 
much greater on BSEP ( Fig. 6 ). Secretion of bile acids 
represents net elimination of cholesterol ( 8 ); therefore, 
induction of BSEP favors lowering cholesterol. In contrast, 
induction of CES1 may favor the elimination or recycling 
of cholesterol, probably depending on the level of CYP7A1 
( Fig. 8B ). Given that the action of CES1 leads to increased 
free cholesterol, high levels of CYP7A1 in individuals 
would facilitate the conversion of cholesterol into bile ac-
ids, whereas low levels of CYP7A1 in others would favor the 
pathway of VLDL assembling (double-lined arrow in 
 Fig. 8B ). Therefore, individuals with a high level of BSEP 
induction relative to CES1 induction (probably with high 
capacity of metabolizing guggulsterones) would benefi t 
more in lowering cholesterol. Accordingly, the purifi ed 
by human microsomes was similar to that by CYP3A4 
( Figs. 4A and 5A ). On the other hand, there were several 
interesting observations, particularly regarding the metabo-
lism by CYP1A2 ( Fig. 4B, C ). Furafylline, an inhibitor of 
CYP1A2, showed little inhibition of Z-guggulsterone me-
tabolism by liver microsomes ( Fig. 4B ), yet recombinant 
CYP1A2 signifi cantly metabolized this phytosterol ( Fig. 4C ). 
One explanation is that Z-guggulsterone is a substrate of 
both CYP3A4 and CYP1A2, but CYP3A4 has higher affi nity 
and more effi ciently metabolizes the phytosterol. In addi-
tion, CYP3A4 is two to three times more abundant than 
CYP1A2 in the liver ( 28 ). Therefore, CYP1A2 normally 
 Fig.  7. Effect of Z-guggulsterone, CDCA, and both on the expres-
sion of mouse bsep, mouse cyp7a1, and esterase activity staining. 
(A) Expression of mouse bsep and cyp7a1. Mouse primary hepato-
cytes (n = 3) were treated with Z-guggulsterone (10   M), CDCA 
(10   M), or both for 24 h. DMSO (0.1%) was used as the control. 
Lysates (25 µg) were resolved by 7.5% SDS-PAGE and transferred 
electrophoretically to nitrocellulose membranes. The blots were 
incubated with an antibody against bsep or cyp7a1, developed with 
chemiluminescent substrate, and reprobed by GAPDH antibody. 
The signal was captured by Carestream 2200 PRO Imager. (B) Non-
denaturing electrophoresis stained for hydrolytic activity. Mouse 
primary hepatocytes and human HepG2 cells were treated as de-
scribed above. Lysates from mouse hepatocytes (5 µg) or HepG2 
cells (20 µg) were subjected to native gel electrophoresis and 
stained for esterase activity with 1-naphythalacetate as described in 
Experimental Procedures. The staining intensity was captured by 
Carestream 2200 PRO Imager. Note the glycosylation variants of 
CES. 
 Fig.  8. Response elements and interplays among CES1, BSEP, 
and CYP7A1. (A) CES1A1 and BSEP guggulsterone response ele-
ments. The antioxidant response elements (ARE) are italicized, 
whereas the activator protein-1 sites (AP-1) are bolded. (B) Multi-
ple interplays among metabolism, CES1/BSEP induction, lipid re-
tention, and bile acid synthesis The arrows point to the targets that 
an enzyme or compound acts on or is converted into. When two 
arrows points to the same target, the solid line denotes a major ef-
fect and the dotted line denotes a minor effect. The double-lined 
arrow denotes an increased role when the induction of CES1 ex-
ceeds the capacity of bile acid synthesis. 
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( Fig. 1B ); and interestingly, the suppression was partially 
reversed by Z-guggulsterone. These fi ndings suggest 
that Z-guggulsterone downregulates CYP7A1 through 
both PXR and FXR, with FXR requiring higher presence 
of bile acids. In addition, Z-guggulsterone and CDCA 
synergistically induced BSEP ( Fig. 1D ), further weaken-
ing the feedback mechanism, although it remains to be 
ascertained whether and to which extent the feed-back 
mechanism contributes to the hypolipidemic activity of 
Z-guggulsterone. 
 In summary, our study presents two interplays that likely 
determine the overall hypolipidemic activity of guggul 
( Fig. 7 ). The fi rst interplay occurs between CES1 induc-
tion and CYP7A1 activity. CES1 induction within the ca-
pacity of CYP7A1 favors the synthesis of bile acids and 
elimination of cholesterol. Excessive induction of CES1 
beyond the capacity of CYP7A1 likely increases the engage-
ment of this enzyme in the hydrolysis/reesterifi cation cy-
cle, favoring VLDL assembly. The second interplay occurs 
between the metabolism of guggulsterones and the induc-
tion of BSEP/CES1. Increased metabolism enhances BSEP 
induction and probably decreases the induction of CES1. 
It is, therefore, expected that individuals with a higher 
capacity of metabolizing guggulsterones (probably lower 
dosing) will show lower induction of CES1 and have better 
hypolipidemic outcomes.  
 The authors appreciate the use of the Core Facility supported 
by National Center for Research Resources, National Institutes 
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